Home › Funds › ORBIMED ADVISORS LLC › ARQT

ORBIMED ADVISORS LLC position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

ORBIMED ADVISORS LLC reported holding 2,042,000 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$53.5M, representing 1.08% of its reported portfolio and ranking #28 among its reported holdings. ORBIMED ADVISORS LLC has disclosed ARQT holdings in 2 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.04M sh
Reported value held$53.54M
Portfolio Weight1.08%
First reportedQ3 2023
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ORBIMED ADVISORS LLC's ARQT position evolved

ORBIMED ADVISORS LLC first disclosed a stake in ARQT in Q3 2023 at 1,914,479 shares (US$10.2M). The position peaked in Q2 2026 at 2,042,000 shares, worth US$53.5M. Across 2 filings, ORBIMED ADVISORS LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 2,042,000 shares valued at US$53.5M.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.91M $10.17M New
Q2 2026 2.04M $53.54M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has ORBIMED ADVISORS LLC held ARQT?

ORBIMED ADVISORS LLC has disclosed ARQT holdings in 2 of the last 12 reported quarters, going back to Q3 2023.

What is ORBIMED ADVISORS LLC's current position in ARQT?

As of Q2 2026, ORBIMED ADVISORS LLC holds 2.04M shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $53.54M, representing 1.08% of its reported portfolio and ranking #28.

Has ORBIMED ADVISORS LLC been buying or selling ARQT?

In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC newly opened its position in ARQT. The position peaked in Q2 2026 at 2.04M shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.